For research and educational purposes only. Not medical advice.
Metformin Reference
Educational, not medical advice reference for Metformin: Metabolic, Longevity; regulatory status, evidence posture, source review, and schedule notes. Also k…
Reference summary
T2D efficacy is robust and the label is mature. The longevity hypothesis rests on observational data (e.g., Bannister 2014 Diabetes Obes Metab reported lower all-cause mortality in metformin-initiated T2D patients vs sulfonylurea-initiated patients) plus animal models. The TAME (Targeting Aging with Metformin) trial has not yet produced a published outcome paper.
Regulatory and posture
- Categories
- Metabolic, Longevity
- Aliases
- Glucophage, 1,1-dimethylbiguanide, Biguanide (small molecule, not a peptide)
- Evidence posture
- human - Off-label longevity use is investigational; the TAME trial has not reported.
- Regulatory status
- FDA-approved for type 2 diabetes (Glucophage NDA 020357, Bristol-Myers Squibb, US approval 1995) and widely available as generic metformin hydrochloride. Off-label longevity use is not FDA-approved and is investigational.
- Content review status
- label verified